Home>>Signaling Pathways>> Tyrosine Kinase>> Src>>MNS

MNS (Synonyms: 3,4Methylenedioxyβnitrostyrene, NSC 10120, NSC 105303, NSC 170724, Syk Inhibitor III)

Catalog No.GC10048

Inhibitor of Src/Syk tyrosine kinases

Products are for research use only. Not for human use. We do not sell to patients.

MNS Chemical Structure

Cas No.: 1485-00-3

Size Price Stock Qty
10mM (in 1mL DMSO)
$45.00
In stock
50mg
$47.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

MNS is a potent and selective inhibitor of Src and Syk tyrosine kinases. target: src, syk. [1]IC50:29.3 (src), 2.5 uM (syk); [1]In vitro: no direct effects on protein kinase C, Ca2+ mobilization, Ca2+-dependent enzymes, PKC activation. MNS potently prevents GPIIb/IIIa activation and platelet aggregation without directly affecting other signaling pathways required for platelet activation. [1] [2] MNS is much more potent than genistein in inhibiting platelet aggregation and protein tyrosine phosphorylation. [2]

References:
[1]. Wang WY et al. Prevention of platelet glycoprotein IIb/IIIa activation by 3,4-methylenedioxy-beta-nitrostyrene, a novel tyrosinekinase inhibitor. Mol Pharmacol. 2006 Oct;70(4):1380-9.
[2]. Wang WY et al. Synthesis and pharmacological evaluation of novel beta-nitrostyrene derivatives as tyrosine kinase inhibitorswith potent antiplatelet activity. Biochem Pharmacol. 2007 Aug 15;74(4):601-11.

Reviews

Review for MNS

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for MNS

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.